The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články, práce podpořená grantem
- MeSH
- absentérství MeSH
- ankylózující spondylitida diagnóza ekonomika epidemiologie terapie MeSH
- balneologie ekonomika MeSH
- časové faktory MeSH
- ekonomické modely MeSH
- lidé středního věku MeSH
- lidé MeSH
- náklady na léky MeSH
- náklady na zdravotní péči * MeSH
- pracovní neschopnost ekonomika MeSH
- prevalence MeSH
- průřezové studie MeSH
- výkonnost MeSH
- zdravotní pojištění ekonomika MeSH
- zdravotnické zdroje ekonomika statistika a číselné údaje MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Geografické názvy
- Česká republika epidemiologie MeSH
To investigate the burden of ankylosing spondylitis in the Czech Republic as a baseline for future health economic evaluations. Data were obtained from two cross-sectional studies Beda I (2005) and Beda II (2008), performed in 1,008 and 509 patients, respectively. Methodology used was Cost-of-Illness prevalence-based analysis bottom-up approach. Analysis was performed from payer (health insurance companies) and societal perspective (including productivity costs using friction cost approach). Mean age of sample in Beda I and Beda II was 50.2 and 52.5 years, male were present by 61.0 and 62.7 %; average disease duration was 23.0 and 26.4 years, respectively. Mean total annual costs per patient in the sample were €4,782 in Beda I and €5806 in Beda II. Average direct costs per patient in the sample per year are estimated at €1,812 (Beda I) and €2,588 (Beda II) with the average productivity costs €2,970 (Beda I) and €3,218 (Beda II). We observed a small decrement in percentage (6.7 %) of productivity costs for Beda II as an influence of higher consumption of biologic drugs, hence higher direct costs and possible productivity preservation. The largest direct cost burdens were spa procedures (45.3 %, Beda I) and biological drugs (52.8 %, Beda II). Unique analysis of the burden of the AS in the Central-Eastern Europe presents health care resource and cost consumption by comparing two cross-sectional prevalence-based studies. Further analysis should be carried to obtain data connecting health status with costs consumption in order to analyse the AS from this perspective.
Zobrazit více v PubMed
J Rheumatol. 1994 Dec;21(12):2286-91 PubMed
Vnitr Lek. 2006 Jul-Aug;52(7-8):726-9 PubMed
Rheumatology (Oxford). 2005 Jul;44(7):939-47 PubMed
Rheumatology (Oxford). 2004 Sep;43(9):1158-66 PubMed
Clin Rheumatol. 2008 Aug;27(8):1005-13 PubMed
Scand J Rheumatol. 2010 Aug;39(4):310-7 PubMed
Pharmacoeconomics. 2011 Aug;29(8):653-71 PubMed
J Rheumatol Suppl. 2006 Sep;78:4-11 PubMed
Ann Rheum Dis. 2002 May;61(5):429-37 PubMed
Ann Rheum Dis. 2003 Sep;62(9):817-24 PubMed
Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv PubMed
Value Health. 2008 May-Jun;11(3):408-15 PubMed
Arthritis Rheum. 1980 Feb;23(2):137-45 PubMed
Value Health. 2010 Jan-Feb;13(1):8-13 PubMed
J Rheumatol. 2006 Feb;33(2):289-95 PubMed
Value Health. 2008 Jul-Aug;11(4):637-44 PubMed
Rheumatology (Oxford). 2008 Jan;47(1):68-71 PubMed
Ann Rheum Dis. 2003 Aug;62(8):732-40 PubMed
Clin Exp Rheumatol. 2006 Sep-Oct;24(5):499-507 PubMed
Ann Rheum Dis. 2006 Apr;65(4):442-52 PubMed
